Welcome to our dedicated page for Marex Group SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Marex Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Marex Group's regulatory disclosures and financial reporting.
Marex Group plc furnished a Form 6-K noting a company press release on insider share activity. On October 15, 2025, the company announced that its directors and officers purchased ordinary shares.
The press release is provided as Exhibit 99.1 titled “Marex announces share purchases by Directors and Officers.”
Marex Group plc filed a Form 6-K reporting that it furnished a press release titled “Marex announces purchase of shares by Chief Executive Officer.” The press release was issued on October 13, 2025.
The release is included as Exhibit 99.1. The filing was signed on the company’s behalf by Chief Financial Officer Robert Irvin on October 14, 2025.
Marex Group plc has submitted a report as a foreign private issuer that mainly serves to share a recent company announcement with U.S. investors. The company attaches a press release dated 8 October 2025 titled “Marex Group plc provides a strong preliminary Q3 trading update,” indicating management views third-quarter 2025 trading performance as strong, although no specific financial figures are included here. The press release is furnished as Exhibit 99.1, and the document is signed on behalf of the company by Chief Financial Officer Robert Irvin.
Marex Group plc (MRX) filed a Form 144 reporting a proposed sale of 56,000 common shares through Goldman Sachs & Co. LLC with an aggregate market value of $1,631,840. The filing shows approximately 71,231,706 shares outstanding and lists an approximate sale date of 10/06/2025. The shares were acquired on 04/29/2016 as restricted stock units paid as compensation. The filer previously sold three blocks of 14,000 shares each on 07/07/2025, 08/04/2025, and 09/02/2025 for gross proceeds of $545,115.20, $530,272.40, and $488,163.20, respectively. The notice includes the standard representation that the seller does not possess undisclosed material information and references Rule 10b5-1 trading-plan language.
Marex Group plc insider notice reports a proposed sale of 12,855 shares of common stock through Goldman Sachs & Co. LLC on 10/06/2025, with an aggregate market value of $374,594.70. The shares were originally acquired as restricted stock units on 12/21/2021 and were granted as compensation. The filer previously sold three blocks of 4,285 shares each on 07/07/2025, 08/04/2025, and 09/02/2025, generating gross proceeds of $166,832.19, $162,239.96, and $149,420.52 respectively. The notice includes the standard Rule 144 representation that the seller is not aware of undisclosed, material adverse information.
Marex Group plc filed a Form 13F reporting its institutional equity holdings. The filing lists 901 Form 13F information table entries with a total value of $11,529,406,132 and identifies 4 other included managers. The report was signed by Jae Cho, Director on 08-18-2025.
Marex Group plc submitted a Form 6-K to provide investors with its interim 2025 financial information. The company furnished a press release titled “Marex Group plc Interim 2025 Results,” issued on 13 August 2025, along with Condensed Consolidated Financial Statements for Marex Group for the six months ended June 30, 2025. These materials are included as Exhibits 99.1 and 99.2, giving readers access to the company’s mid‑year performance details and supporting financial statements.